healthcare

A seemingly minor provision in the federal Inflation Reduction Act enacted last year could make it harder for marginalized patients to access the medicines their doctors have prescribed. It could also prevent the future development of cutting-edge, convenient treatments for many diseases that disproportionately affect communities of color.

After years of urging an end to racial inequity in healthcare for the sake of moral good, a coalition of industry leaders in Massachusetts are taking a new approach: dollars and cents.